# ZUMA-12 (NCT03761056)

> Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03761056
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Kite, A Gilead Company
- Conditions: B-cell Lymphoma
- Interventions: Axicabtagene Ciloleucel; Fludarabine; Cyclophosphamide
- Enrollment: 42
- Primary outcome: Complete Response (CR) Rate Per the Lugano Classification as Determined by Study Investigators

## Commentary we found

- YouTube: 21
- Podcasts: 19
- X threads: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=zuma-12-nct03761056

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03761056", "email": "<work email>"}; the inbox owner confirms by the emailed link.